

San Francisco

Spring Group Meeting

SPECIALS

Immunotherapeutics Committee

Immunotherapeutics Committee

Leadership

Co-Chairs: Siwen Hu-Lieskovan, MD, PhD
 Katerina Politi, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Michael LeBlanc, PhD
 Katie Minichiello, MS
 James Moon, MS
 Matt Chansky, BS

Designates

Data Coordinators: Michele Counts
 Pharmaceutical Science: Jordan P. McPherson, PharmD
 Kimberly McConnell, PharmD
 Sr. Protocol Project Manager: Chris Kippola, BS
 Clinical Trial Program Manager: Laura Gildner, MS

Time/Location

Thursday, May 1, 2025 4:00 p.m. - 6:00 p.m.
 Room: Seacliff AB (Bay Level)

Agenda

4:00 – 4:05 PM **Welcome & Introductions**
Siwen Hu-Lieskovan & Katerina Politi
SWOG Immunotherapeutics Committee Co-Chairs

4:05 – 4:20 PM **iMATCH Pilot Update: Stage II Activation**
Paul Swiecicki, Katerina Politi, Siwen Hu-Lieskovan
S2101 Study Chairs

4:20 – 4:30 PM **Q & A**

4:30 – 4:45 PM **SWOG Translational Medicine Process:
 An Overview**
James Rae, PhD
SWOG Executive Officer for Translational Medicine
Thomas H Simpson Collegiate Professor of Cancer
Research, Associate Professor of Pharmacology,
University of Michigan Medical School

4:45 – 4:55 PM **Q & A**

4:55 – 5:10 PM **Cancer Immune Monitoring and Analysis Centers
 and Cancer Immunologic Data Center
 (CIMAC-CIDC) Network: A Progress Update &
 Development of Translational Medicine Trials**
Cara Haymaker, PhD
Director, ORION Core
Associate Professor, Department of Translational
Molecular Pathology (TMP)
The University of Texas MD Anderson Cancer Center

5:10 – 5:20 PM **Q & A**

5:20 – 5:35 PM **Update: Developing Predictors of
 Immunotherapy using Big Data**
Eytan Ruppin, MD, PhD
Senior Investigator, National Cancer Institute
Chief, Cancer Data Science Laboratory

5:35 – 5:45 PM **Q & A**

5:45 – 5:55 PM **Final Comments & Closing Remarks**
Siwen Hu-Lieskovan & Katerina Politi
SWOG Immunotherapeutics Committee Co-Chairs

Active Study

S2101, "Biomarker Stratified CaboZantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study." Drs. Hu-Lieskovan, Swiecicki and Politi.
 Activation: 10/14/22

Immunotherapeutics Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S2101
Essentia Health NCI Comm Oncology Research Program	1
Froedtert & the Medical College of Wisconsin LAPS	3
Heartland Cancer Research NCORP	1
Michigan Cancer Research Consortium NCORP	1
New Mexico Minority Underserved NCORP	1
Northwestern University LAPS	1
Pacific Cancer Research Consortium NCORP	1
University of Arkansas for Medical Sciences	2
University of Michigan Comprehensive Cancer Center LAPS	13
University of Utah - Huntsman Cancer Institute LAPS	10
ALLIANCE	8
ECOG-ACRIN	7
NRG	5
Total	54

